Oncology & Cancer

Ibrance approval expanded to include men with breast cancer

(HealthDay)—U.S. Food and Drug Administration approval of Ibrance (palbociclib) capsules has been widened to include men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic ...

Oncology & Cancer

Stop marginalising men with breast cancer

Breast cancer is the most common cancer in the UK and the leading cancer in women worldwide. Approximately 150 cases are diagnosed in the UK every day – that's one every 10 minutes. Breast cancer does not discriminate. ...

Oncology & Cancer

Novel gene variants identified in male breast cancer

Male breast cancer (MBC) is a very rare tumor type, occurring in just 1% of all breast cancer cases, and the underlying genetic causes and treatment of MBC is not well understood. In a paper published in the March issue of ...

page 2 from 5